Relay Therapeutics (RLAY) Equity Ratio (2020 - 2025)
Historic Equity Ratio for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to 0.91.
- Relay Therapeutics' Equity Ratio rose 56.98% to 0.91 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.91, marking a year-over-year increase of 56.98%. This contributed to the annual value of 0.89 for FY2024, which is 18.68% up from last year.
- Relay Therapeutics' Equity Ratio amounted to 0.91 in Q3 2025, which was up 56.98% from 0.91 recorded in Q2 2025.
- In the past 5 years, Relay Therapeutics' Equity Ratio registered a high of 0.95 during Q1 2021, and its lowest value of 0.84 during Q2 2023.
- Its 5-year average for Equity Ratio is 0.88, with a median of 0.89 in 2024.
- Within the past 5 years, the most significant YoY rise in Relay Therapeutics' Equity Ratio was 23369.11% (2021), while the steepest drop was 1042.08% (2021).
- Over the past 5 years, Relay Therapeutics' Equity Ratio (Quarter) stood at 0.89 in 2021, then dropped by 2.95% to 0.86 in 2022, then rose by 3.13% to 0.89 in 2023, then grew by 0.19% to 0.89 in 2024, then grew by 1.61% to 0.91 in 2025.
- Its Equity Ratio was 0.91 in Q3 2025, compared to 0.91 in Q2 2025 and 0.9 in Q1 2025.